): The current proposal encompasses 5 years and focuses on identifying new genes, or altered levels of expression of known genes, and possible mechanism(s) of lynphomagenesis in individuals with AIDS. Approximately 5 to 10% of AIDS patients develop non-Hodgkin's lymphoma (NHL), a large number of which are classified by multiple criteria as high grade B-cell immunoblastic lymphoma (BIBL). This investigation utilizes guidance provided by three established researchers, each of whom provides a unique expertise and set of reagents. Early stages utilize Suppression Subtractive Hybridization (SSH) and DNA macro- and microarray gene fragment screening of a BIBL subset of 15 genetically defined AIDS-NHL tissue samples. This BIBL subset lacks EBV and K S HV/HHV-8 infections and also lacks generic lesions or dysregulated expression of any of the proto-oncogenes or tumor suppressor genes frequently found in AIDS-NHL. Dr. C. Denny, whose laboratory routinely employs Representational Difference Analysis (RDA), will guide SSH cDNA-isolation from the BIBL subset and Dr. S. Nelson will provide support for DNA microarray screening technology should it become necessary. Gene products differentially expressed in AIDS-BIBL versus hyperplastic lymph node material will be isolated and used to establish an index set of gene fragments against which other lymphoma and non-lymphomatous samples will be compared. Commonly dysregulated genes will be evaluated by multiple criteria and selected candidates will be checked for cytokine inducibility, cloned, sequenced, and analyzed for relatedness to known sequences. Once obtained, novel and known candidate cDNAs will be moved into CMV-based and inducible expression vector systems containing FLAG epitope tags under the guidance of Dr. R. Wall. These t a g ged cDNA candidate clones will be stably transformed into three immortalized premalignant murine B-cell lines, established previously in the laboratory of Dr. J. Braun. Transformants created with novel cDNAs will be assayed for resistance to NK cytolysis and MHC class I expression, while previously defined cDNAs will be similarly assayed and studied further based o n a v ailable reagents and current knowledge of their function(s). Transformants exhibiting NK cell resistance and elevated MHC class I expression will be evaluated for in vivo tumor formation in Balb/c-scid and syngeneic (BWF1 or AJ9) mice. Tumorigenicity in immune competent and deficient hosts will be assessed by BIBL-FLAG immunohistochemistry, routine h i stology, mortality curves, and organ morphology/weights. Genes with significant involvement in the etiology and/or progression of lymphomagenesis, or those with reproducible in vitro biochemical effects, will be further characterized by molecular methods.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Investigator Award (CIA) (K08)
Project #
1K08CA074929-01A1
Application #
2696351
Study Section
Subcommittee G - Education (NCI)
Program Officer
Gorelic, Lester S
Project Start
1998-09-30
Project End
2003-09-29
Budget Start
1998-09-30
Budget End
1999-09-29
Support Year
1
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Pathology
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Teitell, Michael A (2003) OCA-B regulation of B-cell development and function. Trends Immunol 24:546-53
Teitell, Michael; Richardson, Bruce (2003) DNA methylation in the immune system. Clin Immunol 109:2-5
Patrone, Lisa; Henson, Sarah E; Teodorovic, Jelena et al. (2003) Gene expression patterns in AIDS versus non-AIDS-related diffuse large B-cell lymphoma. Exp Mol Pathol 74:129-39
French, Samuel W; Malone, Cindy S; Shen, Rhine R et al. (2003) Sp1 transactivation of the TCL1 oncogene. J Biol Chem 278:948-55
French, Samuel W; Shen, Rhine R; Koh, Patricia J et al. (2002) A modeled hydrophobic domain on the TCL1 oncoprotein mediates association with AKT at the cytoplasmic membrane. Biochemistry 41:6376-82
French, Samuel W; Hoyer, Katrina K; Shen, Rhine R et al. (2002) Transdifferentiation and nuclear reprogramming in hematopoietic development and neoplasia. Immunol Rev 187:22-39
Su, Thomas T; Guo, Beichu; Kawakami, Yuko et al. (2002) PKC-beta controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling. Nat Immunol 3:780-6
French, Samuel W; Dawson, David W; Miner, Mindy D et al. (2002) DNA methylation profiling: a new tool for evaluating hematologic malignancies. Clin Immunol 103:217-30
Arvand, A; Welford, S M; Teitell, M A et al. (2001) The COOH-terminal domain of FLI-1 is necessary for full tumorigenesis and transcriptional modulation by EWS/FLI-1. Cancer Res 61:5311-7
Said, J W; Hoyer, K K; French, S W et al. (2001) TCL1 oncogene expression in B cell subsets from lymphoid hyperplasia and distinct classes of B cell lymphoma. Lab Invest 81:555-64

Showing the most recent 10 out of 12 publications